Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Google Inc (GOOG) Misses Q3 Earnings on Accidental Release

Google Inc (NASDAQ:GOOG)‘s shares are down close to 9% after the tech giant mistakenly released its third quarter earnings around lunchtime. The company missed the Street’s estimates quite significantly, as analysts were expecting it to reach EPS of $10.65 a share; Google Inc (NASDAQ:GOOG) reached just $9.03 a share. The miss of more than 15% comes after Google Inc (NASDAQ:GOOG) beat earnings estimates in Q1 and Q2 by an average margin of 2.3%.

Google Inc (GOOG)

The company, which has been in patent litigation with Vringo, Inc. (NYSEAMEX:VRNG) this week, realized a big loss from Motorola Mobility, which was acquired earlier this year. The segment generated an adjusted loss of over $151 million for Google Inc (NASDAQ:GOOG).

Due to the miss, Google’s Q3 EPS is down more than 7% year-over-year. The company’s stock currently trades at a modest PEG of 1.33 and a trailing P/E of 22.4X. Google’s five-year historical average earnings multiple is nearly 25% higher at 30.0X, and the Internet content and information industry’s average P/E is just over 28.0X. Check out our comprehensive database to see which hedge funds are holding Google Inc (NASDAQ:GOOG).

Disclosure: I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours.

Biotech Insider Alert - $5 Stock To Hit $40

$200 Million Dollar Healthcare Hedge Fund's #1 Best Idea Right Now

The best healthcare hedge fund out there right now is one of the largest shareholders in this biotech stock. The fund returned more than 20% in each of the last 2 years with a virtually fully hedged portfolio, and it's sending out a BUY signal on this biotech stock. Get your FREE REPORT today (retail value of $300)

Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.
Loading Comments...
X

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!